Evaluation of new nanotechnology to raise HDL cholesterol level and elucidation of its molecular mechanism

提高HDL-胆固醇（C）已成为一种潜在的策略，以解决即使在降低LDL-C和甘油三酯后仍然存在的残余风险，以预防心血管疾病。聚乙二醇化和季铵化聚胺纳米凝胶（Q-Nanogel）是一种新合成的胆盐螯合剂，用于治疗血脂异常。我们评估了Nanogel对血脂异常和动脉粥样硬化的影响。纳米凝胶治疗导致C57 BL/6 J小鼠血浆VLDL/LDL-C水平降低35%，血浆HDL-C水平增加58%。在LDLR-/-小鼠中，与PBS相比，使用Nanogel的动脉粥样硬化病变大小减少了45%。这些数据表明，Nanogel不仅降低了VLDL/LDL-C水平，还提高了HDL-C水平。纳米凝胶可能是一种潜在的治疗候选人，以提高HDL-C和动脉粥样硬化的治疗。

Raising HDL-cholesterol (C) has emerged as a potential strategy to tackle the residual risk that remains even after lowering LDL-C and triglyceride, in preventing cardiovascular disease. PEGylated and quaternized polyamine nanogel (Q-Nanogel) is a newly synthesized bile salt sequestering agent intended to treat dyslipidemia. We assessed the effects of Nanogel on dyslipidemia and atherosclerosis. Nanogel treatment resulted in a 35% reduction in plasma VLDL/LDL-C levels, a 58% increase in plasma HDL-C levels in C57BL/6J mice. In LDLR-/-mice, atherosclerotic lesion size with Nanogel was reduced by 45% compared to PBS. These data indicate that Nanogel not only decreased VLDL/LDL-C levels but also raised HDL-C levels. Nanogel could be a potential therapeutic candidate to raise HDL-C and the treatment of atherosclerosis.